Evidence map›Paper›PMID 39684655›Full record

ArticleInternational journal of molecular sciences2024

Advanced PROTAC and Quantitative Proteomics Strategy Reveals Bax Inhibitor-1 as a Critical Target of Icaritin in Burkitt Lymphoma.

Peixi Zhang, Ziqing Zhang, Jie Li, Meng Xu, Weiming Lu, Ming Chen, Jiaqi Shi, Qiaolai Wang, Hengyuan Zhang, Shi Huang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Peixi ZhangSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Ziqing ZhangSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Jie LiSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Meng XuSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Weiming LuSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Ming ChenSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Jiaqi ShiSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Qiaolai WangSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Hengyuan ZhangSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Shi HuangSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Chenlei LianSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Jia LiuSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Junjie MaSchool of Medicine, Huaqiao University, Quanzhou 362021, China.ORCID 0000-0001-5844-9984
Jieqing LiuSchool of Medicine, Huaqiao University, Quanzhou 362021, China.

Funding

Fujian Provincial Industry-University Cooperation Project No. 2021Y4012National Natural Science Foundation of China No. 21772047Open research topics of Fujian Provincial Key Laboratory of Marine Algae Active Substances Preparation and Functional Development No. 2022-KF04QuanZhou High Level Talent Innovation and Entrepreneurship Project No. 2023C003R
6 · The paper itself

Abstract

Understanding the molecular targets of natural products is crucial for elucidating their mechanisms of action, mitigating toxicity, and uncovering potential therapeutic pathways. Icaritin (ICT), a bioactive flavonoid, demonstrates significant anti-tumor activity but lacks defined molecular targets. This study employs an advanced strategy integrating proteolysis targeting chimera (PROTAC) technology with quantitative proteomics to identify ICT's key targets. A library of 22 ICT-based PROTAC derivatives were synthesized, among which

Indexed as

ApoptosisBurkitt LymphomaFlavonoidsProteolysisProteomicsApoptosis Regulatory ProteinsCell Line, TumorEndoplasmic Reticulum StressHumansMembrane ProteinsMolecular Docking SimulationApoptosis Regulatory ProteinsFlavonoidsicaritinMembrane Proteinsanti-tumoricaritinmechanism of actionPROTACsquantitative proteomicstarget identification

Identifiers

PMID39684655
PMCPMC11641208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.